Compare CNXN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | IMCR |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1997 | 2016 |
| Metric | CNXN | IMCR |
|---|---|---|
| Price | $66.89 | $29.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $66.33 |
| AVG Volume (30 Days) | 48.8K | ★ 366.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 0.68 | 0.25 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $6.24 | $14.57 |
| Revenue Next Year | $4.39 | $8.21 |
| P/E Ratio | ★ $96.28 | $122.22 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $54.97 | $27.47 |
| 52 Week High | $71.17 | $40.71 |
| Indicator | CNXN | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 47.99 |
| Support Level | $56.14 | $28.23 |
| Resistance Level | $66.89 | $34.35 |
| Average True Range (ATR) | 1.70 | 1.35 |
| MACD | 0.08 | 0.16 |
| Stochastic Oscillator | 87.35 | 53.87 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.